Clinically Isolated Syndrome Clinical Trial
Official title:
A Pilot Study to Investigate Glymphatic System Alterations in Vivo in Patients With Clinically Isolated Syndrome, Using Magnetic Resonance Imaging
The brain possesses a system to get rid of unwanted substances, named Glymphatic System (GS). When this system is faulty, these accumulate, there is local inflammation, and progressive death of the cells. This occurs in neurological diseases including Parkinson's, or Alzheimer's. Inflammation and progressive death of the cells are also present in another neurological disorder, named Multiple Sclerosis (MS). Doctors think that GS dysfunction plays a role in MS too. In this research therefore, the aim is to study whether it drives inflammation, and disease progression in MS patients. The researchers have developed a new way to find signs of alteration of the GS using a scan named Magnetic Resonance Imaging (MRI) and will use it in a pilot study on patients with a condition named Clinically Isolated Syndrome (CIS), which often represents the very beginning of MS. It would therefore be demonstrated that the GS is a new mechanism of disease in CIS, which may associate with the symptoms, or the alterations in the levels of some substances in the blood suggestive of brain cells damage. Should this study be successful, this would provide preliminary evidence to perform a larger research study to assess if GS dysfunction drives the progression of MS.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | May 15, 2025 |
Est. primary completion date | May 15, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female, aged 18 or over 2. Suitable physically and psychologically to undertake the assessments, as judged by the Investigator 3. Have voluntarily provided informed consent and have signed an ICF indicating that the purpose of the study has been explained and are willing and able to adhere to the study procedures described in the ICF. 4. (For CIS group): A diagnosis of CIS or MS at first presentation 5. Subjects must not have taken corticosteroids or IVIg or plasma-exchange within the 30 days prior to consent 6. Adequate vision and hearing to perform the study procedures 7. Medically healthy with no clinically significant findings on physical examination, laboratory profiles, vital signs at screening (with the exception of the signs of the condition under investigation) 8. Women of child-bearing potential must practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, or double-barrier method (condom or intrauterine device with spermicide). 9. If on immunomodulatory medication, patients must have started it at least 30 days from screening and should not change their medication dose for the duration of the study. Exclusion Criteria: 1. Have a diagnosis of clinically definite Multiple Sclerosis according to the 2017 McDonald's Criteria (Thompson et al., 2018) 2. Have a CIS limited to the spinal cord (transverse myelitis) 3. Present psychiatric disorders or severe cognitive deficit 4. Past or present history of drug or alcohol abuse 5. Are pregnant or breastfeeding, if females of childbearing potential 6. Have any other medical, neurological, or psychiatric condition or clinically significant laboratory abnormality excluding CIS which, in the opinion of the Investigator, might preclude participation 7. Are taking benzodiazepines on a regular basis or are unable to suspend intake of benzodiazepines 8. Have received any investigational product within a time-period equal to five half-lives of the product, if known, or minimum of 60 days before consent 9. Are unable to lie down for MRI scanning 10. Have any finding on the brain MRI that would compromise subject safety or the scientific integrity of the study 11. Have implants, such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, aneurysm clips, or other medical implants that have not been deemed safe for MRI 12. Have a history of claustrophobia 13. Have any other contraindication to MRI scanning 14. Have a relapse occurred after consent but before the MRI scan 15. It is preferable the following laboratory tests are part of the subject's medical history for differential diagnosis of clinically isolated syndrome (CIS): erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), complement (C3, C4) and anticardiolipin IgG - IgM |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Exeter | Exeter |
Lead Sponsor | Collaborator |
---|---|
University of Exeter |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine that patients with CIS display alterations of the glymphatic system visible in vivo by Structural MRI | Difference between CIS and HV in the number of perivascular spaces | Through study completion, an average of 7 days | |
Primary | To determine that patients with CIS display alterations of the glymphatic system visible in vivo by microstructural MRI | Difference between CIS and HV in estimation of intraparenchymal water transport | Through study completion, an average of 7 days | |
Primary | To determine that patients with CIS display alterations of the glymphatic system visible in vivo by diffusion-weighted MRI | Difference between CIS and HV in the calculation of the ALPS-index | Through study completion, an average of 7 days | |
Primary | To determine that patients with CIS display alterations of the glymphatic system visible in vivo by perfusion-MRI | Difference between CIS and HV in estimation of choroid plexus perfusion | Through study completion, an average of 7 days | |
Primary | To determine that patients with CIS display alterations of the glymphatic system visible in vivo by ALS-MRI | Difference between CIS and HV in estimation of Cerebrospinal Fluid (CSF) flow | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system with MRI measures of structural integrity in CIS | Quantification in CIS of structural volumetric and thickness | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system with MRI measures of disease activity in CIS | Quantification in CIS of total lesion load | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system with MRI measures of enlarged Wirchow-Robin spaces in CIS | Quantification in CIS of perivascular spaces | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system with MRI measures of microstructural altertions in CIS | Quantification in CIS of free water, a measure of extracellular space | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system with MRI measures of brain perfusion in CIS | Quantification in CIS of water transport and regional perfusion. | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system in CIS with clinical measures of disease severity | Correlation between MRI measures and EDSS score in CIS patients. | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system in CIS with fluid biomarkers of axonal injury in CIS | Correlation between MRI measures and fluid biomarkers for neuroaxonal integrity (calculated with the quantification of Neurofilament Light Chain (NfL) | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system in CIS with fluid biomarkers of astrocytis integrity in CIS | Correlation between MRI measures and fluid biomarkers for astrocytic activation (calculated with the quantification of Glial Fibrillary Acid Protein (GFAP) | Through study completion, an average of 7 days | |
Secondary | To correlate in vivo measures of altered glymphatic system in CIS with fluid biomarkers of glymphatic activity in CIS | Correlation between MRI measures and fluid biomarkers for glymphatic transport damage (calculated with the quantification of Aquaporin 4 (AQP4) and of Neuronal-Specific Enolase (NSE) | Through study completion, an average of 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT03979391 -
Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome
|
N/A | |
Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
Recruiting |
NCT03541226 -
Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)
|
||
Active, not recruiting |
NCT04998851 -
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
|
Phase 4 | |
Recruiting |
NCT05277740 -
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
|
||
Recruiting |
NCT03004079 -
Clinical Importance of Glucose Regulation in Relapsing MS
|
||
Completed |
NCT02043964 -
Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion
|
N/A | |
Completed |
NCT00287079 -
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
|
Phase 3 | |
Terminated |
NCT04599023 -
Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System
|
||
Completed |
NCT01728922 -
Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT01737372 -
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
|
N/A | |
Terminated |
NCT00595920 -
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
Completed |
NCT04705610 -
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
|
N/A | |
Recruiting |
NCT03610139 -
Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients
|
N/A | |
Active, not recruiting |
NCT04009005 -
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
|
N/A | |
Not yet recruiting |
NCT06280755 -
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
|
||
Completed |
NCT03872583 -
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
|
N/A | |
Terminated |
NCT00819897 -
Longitudinal Study in Clinically Isolated Syndrome (CIS) Patients Treated With Interferon Beta
|
N/A |